Automatic interactive optimization for volumetric modulated arc therapy planning by unknown
Tol et al. Radiation Oncology  (2015) 10:75 
DOI 10.1186/s13014-015-0388-6RESEARCH Open AccessAutomatic interactive optimization for volumetric
modulated arc therapy planning
Jim P Tol1*, Max Dahele1, Jarkko Peltola2, Janne Nord2, Ben J Slotman1 and Wilko FAR Verbakel1Abstract
Background: Intensity modulated radiotherapy treatment planning for sites with many different organs-at-risk
(OAR) is complex and labor-intensive, making it hard to obtain consistent plan quality. With the aim of addressing
this, we developed a program (automatic interactive optimizer, AIO) designed to automate the manual interactive
process for the Eclipse treatment planning system. We describe AIO and present initial evaluation data.
Methods: Our current institutional volumetric modulated arc therapy (RapidArc) planning approach for head and
neck tumors places 3-4 adjustable OAR optimization objectives along the dose-volume histogram (DVH) curve that
is displayed in the optimization window. AIO scans this window and uses color-coding to differentiate between the
DVH-lines, allowing it to automatically adjust the location of the optimization objectives frequently and in a more
consistent fashion. We compared RapidArc AIO plans (using 9 optimization objectives per OAR) with the clinical
plans of 10 patients, and evaluated optimal AIO settings. AIO consistency was tested by replanning a single patient
5 times.
Results: Average V95&V107 of the boost planning target volume (PTV) and V95 of the elective PTV differed by ≤0.5%,
while average elective PTV V107 improved by 1.5%. Averaged over all patients, AIO reduced mean doses to individual
salivary structures by 0.9-1.6Gy and provided mean dose reductions of 5.6Gy and 3.9Gy to the composite swallowing
structures and oral cavity, respectively. Re-running AIO five times, resulted in the aforementioned parameters differing
by less than 3%.
Conclusions: Using the same planning strategy as manually optimized head and neck plans, AIO can automate the
interactive Eclipse treatment planning process and deliver dosimetric improvements over existing clinical plans.
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An important goal in radiotherapy treatment planning is
relatively homogenous irradiation of the planning target
volumes (PTVs) whilst minimizing dose to nearby
organs-at-risk (OARs). In many situations, especially
when there is a complex OAR - PTV geometry, this can
be achieved using some form of intensity modulated ra-
diation therapy (IMRT), including volumetric modulated
arc therapy (VMAT). Planning IMRT and VMAT treat-
ments requires optimization of multileaf collimator
(MLC) leaf positions to achieve suitable dose distribu-
tions. Different treatment planning systems (TPS’s) offer* Correspondence: j.tol@vumc.nl
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unless otherwise stated.different algorithms and interfaces to perform this
optimization. For instance, some TPS’s allow for inter-
active optimization, which involves presenting dose-
volume histograms (DVHs) to the user and dynamically
updating them while the user adapts specific dose-
volume objectives during optimization. Ultimately, many
factors influence the final treatment plan, including
acceptance criteria for PTV dose coverage and homo-
geneity, optimization objectives and weightings for OARs
and PTVs. If the specific TPS allows for interactive
optimization, the experience of the planner, along with the
interaction between the planner and the TPS, can also in-
fluence the obtained plan quality and may contribute to
large variations between planners and centers [1,2].
Treatment planning has become increasingly complex
over the years, particularly regarding the number ofs is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ample, radiotherapy treatments for head and neck can-
cer evolved from essentially contralateral parotid gland
and spinal cord sparing [3] to include sparing of the ipsi-
lateral parotid gland, the contralateral submandibular
gland, multiple swallowing muscles and the oral cavity
[4]. This further increases the difficulty of plan
optimization and increases the likelihood that incon-
sistent planning results are obtained between planners.
Automated planning techniques might assist in reducing
such variation and allow for the creation of more consist-
ent and high quality plans. Although automated planning
is in its infancy, promising results have already been
obtained using knowledge-based planning [5-13] and
automated multicriteria plan optimization [14-16].
One of the most commonly used TPS’s is Eclipse™
(Varian Medical Systems, Palo Alto, USA) which allows
for interactive optimization of IMRT and VMAT plans.
In our experience, when trying to create a plan that pro-
vides maximum OAR sparing for an individual patient
(as opposed to creating plans where optimization stops
once a pre-determined level of OAR sparing has been
achieved, regardless of whether or not it could be im-
proved upon for a given patient), the lowest achievable
OAR doses and the trade-off between OAR sparing and
PTV dose homogeneity [17] are typically not known in
advance of making the plan. This means that the optimal
settings of the optimization objectives have to be deter-
mined during planning. This can be done during inter-
active optimization. As a result, interaction between the
planner and the TPS is a key step in producing a good
plan, while at the same time it presents a source of
considerable variation in the manual planning process.
We propose a novel approach to automate interactive
VMAT planning using the Eclipse TPS that aims to ad-
dress the increasing challenges of manual planning and
attempts to meet the competing demands for consistent
and high quality planning under conditions of increasing
complexity, while limiting the total planning time. We
believe that these challenges are common to many cen-
ters, especially where the creation of complex treatment
plans is concerned. This report describes our automatic
interactive optimizer solution (AIO) and presents an ini-
tial evaluation of its performance.
Methods
AIO was evaluated by creating simultaneous integrated
boost plans for ten head and neck cancer patients that
were previously treated using RapidArc®. RapidArc is the
VMAT approach of Varian Medical Systems, based on
the work of Otto [18]. Prescribed doses were 54.25Gy to
the elective PTV (PTVE) and 70Gy to the boost PTV
(PTVB) in 35 fractions of 1.55Gy and 2Gy, respectively.
A 5mm transition zone (PTVT) was created betweenPTVB and PTVE to facilitate a dose fall-off between
them. Table 1 shows the tumor site, stage and PTV vol-
umes for each patient. For optimization and reporting
purposes, a 6mm ‘virtual’ bolus region was used to ob-
tain adequate target coverage in areas where the PTV
approached the surface [19].
In all plans included in this study, optimization was
performed using the progressive resolution optimizer
(PRO) version 10.0.28 and followed by a ‘continue previ-
ous optimization’ (CPO) to improve PTV dose homo-
geneity [17]. Dose calculation was performed using the
anisotropic analytical algorithm (AAA) version 10.0.28
with a 2.5mm grid size.
The Progressive Resolution Optimizer (PRO)
PRO is used to optimize the MLC apertures of arc fields
in a treatment plan. A multi-resolution (MR) model is
used, meaning that the angular dose representation
starts with a crude approximation that gets finer as the
optimization progresses [20]. Input parameters are geo-
metric characteristics of each field and a set of
optimization objectives, see below, that can be adapted
at any point during the optimization. The output of the
optimizer is a control-point (cp) sequence, defining
MLC configuration and MU count at each of the arc’s
178 control points. Each structure’s DVH-line is
displayed and can be manipulated by adapting the
optimization objectives, to attempt to meet clinical
goals for PTV dose coverage and OAR doses. Each
optimization objective has four input parameters: an
optimization priority (P), a 2D-position on the DVH-
graph representing the dose and volume goal (dosegoal,
volumegoal), and information describing whether the
dosegoal is an upper (maximum) or lower (minimum) dose
limit for the structure’s DVH-curve.
The objective weighting (objectiveweight) is derived
from P using a heuristic power law-formula. A doubling
of P results in a 32 time multiplication of weightobjective.
To reduce the occurrence of hot and cold spots, PRO
also increases objectiveweight for objectives with volumegoal
values of 0% or 100%.
Each point (i) inside a structure, not fulfilling the ob-
jective, gets assigned a penalty cost. A structure with n









The cost for an objective j is only taken into account
for the range of voxels that violate the assigned dose-
volume criteria. For example, if dosegoal and volumegoal
are set to <5Gy and 10%, respectively, 10% of the struc-
ture volume may have doses higher than 5Gy without
Table 1 Detailed information of the included head and neck cancer patients





† (cm3) Oral cavity (cm3)
1 Larynx T2N2c 428.7 93.7 243.3 66.7 7.1 -
2 Oropharynx T2N2b 441.7 48.3 188.6 82.3 16.5 -
3 Oropharynx T2N2a 240.6 43.4 94.5 42.4 25.0 -
4 Oropharynx T4N1 288.2 57.3 237.5 60.6 10.6 -
5 Oropharynx T4aN1 280.8 79.5 164.5 78.9 32.0 36.7
6 Oropharynx T4aN2b 288.2 57.3 237.5 60.6 10.6 14.6
7 Oropharynx T4aN1 360.4 62.9 143.7 73.0 35.0 57.1
8 Oropharynx T3N1 500.3 87.9 231.7 55.0 11.9 29.4
9 Oropharynx T4aN2c 258.4 155.7 328.9 38.3 4.8 38.1
10 Hypopharynx T2N3 264.0 137.0 607.0 70.8 10.3 60.6
The disease site, stage and volumes of the elective, transition and boost planning target volumes (PTVE, PTVT, PTVB respectively) and the volumes of the
composite salivary and swallowing structures for all patients. The oral cavity was included as an organ-at-risk in 6/10 patients.
Abbreviations:
*Compsal = Composite salivary glands. Depending on degree of overlap with the PTVs and choice for inclusion by the treating clinician, compsal could consist of
some, or all, of the ipsilateral and contralateral parotid and submandibular glands.
†Compswal = Composite swallowing muscles. Could consistent of some, or all, of the upper esophageal sphincter, upper and lower parts of the larynx, the superior,
medial and inferior pharyngeal constrictor muscle, the cricopharyngeal muscle and the esophagus.
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violated, the cost function is calculated for the structure
points with dosei values ranging from 5Gy to the dose
achieved at 10% volume of the DVH-curve, see Figure 1.
The total cost function value is calculated by summing
equation (1) over all structures that are included in the
PRO optimization.
During optimization, new, mutated MLC configura-
tions that result in the largest decrease to the total cost
function are successively added to the control points. InFigure 1 Local force exerted on the DVH-curve by two optimization o
(blue triangles) exerting force on the DVH-line (yellow area). Because struct
dose-volume criteria are violated, the objectives can lower the DVH-curve l
calculating the cost function, with dosei values ranging from 50-58Gy. Beca
included structure points is larger (35%), with doses ranging from 30-40Gy.
points would contribute to two separate cost functions.the first MR-level, the optimizer divides the arc into
eleven 16-cp long sequences. The optimizer randomly
selects 8 sequences and makes simultaneous changes to
MLC configurations, while taking into account physical
limitations such as MLC leaf speed, gantry speed and
dose rate. Three subsequent increases in the MR-level
increase the number and while decreasing the size of
these cp-sequences to 22 times 8-cps, 44 times 4-cps
and finally 88 times 2 cps. Changes in positioning of the
MLC leafs are dictated by set of 0-8 cp-sequences foundbjectives. A schematic representation of two optimization objectives
ure points only contribute to an objective’s cost function if the set
ocally. Objective A contributes 13% (33%-20%) of structure points to
use objective B is placed further from the DVH-curve, the number of
In case of overlap between the yellow areas, the included structure
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These changes are incorporated into the subsequent iter-
ations. At the start of each iteration, the optimization
objectives, which might have been changed, are sent to
the PRO algorithm, allowing it to find more optimal
MLC configurations to satisfy the set objectives. If the
total cost function has converged, the optimization auto-
matically proceeds to the next MR-level. The user can
pause the automatic progression to subsequent MR-
levels allowing the user more time to make changes to
the dose-volume objectives. In the earlier MR levels, PRO
is more flexible towards changes in the optimization goal
during optimization, as it can make large changes in the
MLC leaf configurations at each iteration. The possibility
to adjust to changed dose-volume objectives gets smaller
in later MR levels as the modified cp-sequence length
decreases.
Optimization using dose-volume objectives
Due to the power-law nature of the objective weightings,
structures with higher prioritized objectives will have
substantially more influence on the resulting plan.
In our clinical planning protocol, described below,
optimization objectives of PTV structures are assigned
higher priorities values than OAR objectives. OAR ob-
jectives can therefore be gradually pushed to lower dose
values at each iteration during optimization without sig-
nificantly affecting the DVH’s of the PTVs. This conceptFigure 2 Eclipse optimization window for a simple head and neck can
cancer patient showing DVH-lines and optimization objectives of the electi
right parotids).forms the basis of our institutional approach to manual
interactive optimization and our automation of it, ex-
plained below.
Interactive optimization
PRO uses a simplified fast dose calculation algorithm to
display DVH lines during the optimization process
(Figure 2), visualizing changes in PTV and OAR doses
while optimization of the MLC leaf positions is being
performed. As previously explained, the priority and dis-
tance (i.e. dose difference) of an optimization objective
to its corresponding DVH-line determines the ‘effort’
made by the optimization algorithm to meet this object-
ive. Initial evaluation of the algorithm during the clinical
introduction of RapidArc at our department in 2008
resulted in the current institutional planning approach
for head and neck tumors [21-23]. Because the patient-
specific favorable dose-volume values of the OAR
optimization objectives are typically not known at start
of planning, this approach involves continuous user
interaction, adapting the location of the OAR objectives
so that they maintain a certain diagonal distance to their
respective DVH-line while the optimization progresses
through the different MR-levels. Parallel OAR, such as
the parotid glands, submandibular glands and swallow-
ing muscles, typically have 4-5 objectives, distributed
along the volume axis of the DVH (prioritized at 80-90,
but can be lowered for individual OAR after discussioncer patient. Eclipse optimization window for a simple head and neck
ve and boost PTVs, spinal cord and brainstem, and two OARs (left and
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actively adjusted. Serial OAR such as the spinal cord and
brainstem, have a single maximum point dose objective
that remains unchanged during optimization. Objectives
for the PTVs have priority values of 130 and remain un-
changed during planning. Interactively adapting multiple
objectives along a DVH results in equal effort/attention
directed at sparing over the entire volume range and
works well for parallel OAR in which the mean dose has
been demonstrated to correlate with toxicity [24,25].
Since continuous pulling of the OAR objectives could
lead to local underdosage of the PTVs near those OARs,
parts of the PTV within 5mm of the OARs are defined
as an extra PTV volume with separate minimum dose
objectives. Interactive optimization using this approach
creates treatment plans with a high probability of satisfy-
ing our institutional guidelines for coverage and homo-
geneity of the PTV. The aims are that at least 99% of the
boost volume is covered with 95% of the prescribed dose
(V95 ≥ 99%) and no more than 4% should receive a dose
greater than 107% (V107 ≤ 4%). Corresponding aims for
the elective volume are V95 ≥ 98% and V107 ≤ 15%.Figure 3 Flowchart of the automatic interactive optimizer (AIO).Head and neck cancer treatment plans currently in-
clude 2 PTVs planned to receive different doses, and up
to 12 individual salivary and swallowing structures are
routinely used. In addition, the oral cavity was included
during optimization for 6/10 patients. Because so many
OARs are included, the continuous manual adjustment
of multiple optimization objective locations along nu-
merous DVH lines has become increasingly challenging.
Automatic optimization solution
An automated alternative to manual interaction was
developed to interactively optimize a large number of
OARs consistently (automatic interactive optimizer,
AIO). AIO was coded in Lazarus, a free Pascal compiler
(http://www.lazarus.freepascal.org/). The flowchart in
Figure 3 provides an overview of an automated
optimization using AIO. Because Eclipse does not allow
for modifications of the optimization algorithm and
interface, AIO was designed to take over interactivity of
the user by automatically moving the cursor and adapt-
ing the position of the OAR objectives on the screen.
If Eclipse would permit access to the optimization
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the optimizer itself.
Before the PRO optimization is started, the user inputs
the coordinates of the optimization window (step 1,
Figure 3), AIO scans this window determining the initial
location of all OAR objectives (step 2, Figures 3 and 4A).Figure 4 Different stages of optimization using the automatic interac
optimization objectives along with the graphical user interface of the AIO.
being performed on a complex head and neck case. C) shows the optimiz
took approximately 29 minutes. Shown abbreviations: PTV = Planning targe
esophageal sphincter.Because color-coding is used to differentiate between
the various OAR objectives, each OAR should be
assigned a unique color. When the optimization is
started (step 3, Figure 3), AIO scans the optimization
window and determines the location of every DVH-line
(step 4, Figure 3), based on the unique color of eachtive optimizer (AIO). A) shows the initial position of all OAR
B) shows the optimization window after 3 minutes while the AIO is
ation window after 11 minutes. In this case, the full optimization
t volume, PCM = Pharyngeal constrictor muscle and UES = Upper
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diagonal pixel distance (the so-called ‘objective-line’
distance [OLD]) from the respective DVH-line (step 5,
Figures 3 and 4B&C). Because AIO moves the
optimization objectives as soon as the DVH-lines appear
on the screen, their initial locations do not influence the
resulting plan quality. If the new objective position is
already occupied with a different optimization objective,
AIO searches for the next available position while keep-
ing a minimum distance of 20 pixels between the objec-
tives to avoid overlap. To allow convergence of the cost
function and let PRO advance to the next MR-levels in
the optimization process, AIO is paused for T seconds
(step 6, Figure 3), after which steps 3-5 are repeated
until PRO completes the RapidArc optimization (step 7,
Figure 3).
By automatically determining the position of the OAR
DVH-lines and repositioning the optimization objectives,
AIO removes the limitation that is posed by the relative
knowledge/experience, precision and attention of the
planner in the interactive planning process, allowing far
more frequent and consistent updating of the OLD. If
the OLD value is equal for each OAR, consistent posi-
tioning of the optimization objectives using AIO results
in a constant cost function for each OAR objective
throughout the optimization process. This allows PRO
to balance sparing of the various OARs, depending on
the assigned optimization priorities. The OLD and PTV/
OAR optimization priorities can be adjusted in order to
meet user-specific criteria for PTV dose coverage and
homogeneity [26]. Additionally, because the location of
every OAR objective is adjusted automatically, more
optimization objectives can be used simultaneously
throughout the optimization. Since the dosegoal and
volumegoal values of these objectives determine the range
of dose values taken into account when calculating the
cost function (see Figure 1), distributing optimization
objectives over the entire volume range may offer im-
proved sparing compared to using 3-4 objectives per
OAR.
Evaluation endpoints
For each patient, the manually optimized (clinical) plan
is compared to the (nominal) AIO plan created using 9
different optimization objectives per OAR, an OLD
value of 50 pixels and a pause time T of 15 seconds. The
OLD value is screen-dependent, a value of 50 was
chosen to reflect the OLD used clinically and corre-
sponds to roughly 5% of the width of the optimization
window at a screen resolution of 1980x1080 pixels. In
the AIO plans, the optimization priorities of PTV and
OAR objectives are kept equal to those used in the clin-
ical plans. To investigate consistency of AIO plans, a
single patient was re-planned 5 times using the sameAIO settings. To determine the influence of the initial
placement of the optimization objectives on the resulting
plan, optimization of 5 patients was performed again
without interactively repositioning the optimization ob-
jectives. The resulting optimization objectives in the
nominal AIO plans were used as the initial location of
the optimization objectives in these non-interactively op-
timized plans, and remained unchanged throughout the
optimization.
To evaluate resulting plan quality when using different
settings of the AIO, additional plans were created using
(i) 3 and 6 planning objectives per OAR, (ii) OLD values
of 25 and 75 pixels and (iii) pause times of 7.5 and
30 seconds while the other parameters were kept at the
aforementioned values.
The following dosimetric parameters were evaluated
after normalizing the AIO plans to deliver the same
mean dose to PTVB as the respective clinical plan:
1) Mean doses to the oral cavity (DOC), individual and
composite salivary glands (Dsal) and swallowing muscles
(Dswal), 2) PTVB and PTVE volumes receiving less than
95% (V95) and more than 107% (V107) of the prescribed
dose. The size of the oral cavity, composite salivary
(compsal) and swallowing structures (compswal) is shown
in Table 1. To determine whether improved sparing
using AIO resulted in increased dose deposition in the
remainder of the body, the mean dose to a body-PTV
structure (obtained by subtracting the combined PTV
from the body contour) was determined, along with
the body-PTV volume receiving >5Gy (V5Gy), >30Gy
(V30Gy) and >50Gy (V50Gy).
Results
AIO and clinical plan results were averaged over all 10
patients and summarized in Table 2. Maximum spinal
cord and brainstem doses were similar and considered
clinically acceptable in all plans. Although PTVB and
PTVE V95 values were marginally worse, consistently
improved OAR sparing was obtained in the nominal
AIO plan that used an OLD of 50 pixels, 9 optimization
objectives per OAR, and a pause time T of 15 seconds.
Compared to the clinical plan, the nominal AIO plan re-
duced mean dose to individual salivary structures by on
average 0.9-1.6Gy, and reduced Dsal from 26.2 ± 5.5Gy
to 25.0 ± 5.8Gy. The oral cavity and individual swal-
lowing muscles saw a larger dose reduction, with com-
posite metrics DOC/Dswal decreasing by 3.9Gy/5.6Gy,
on average. This increased OAR sparing using AIO
came at the expensive of a 0.1% higher body-PTV
mean dose on average, while V5Gy, V30Gy and V50Gy
were respectively 0.2%, 0.4% and 0.4% higher. AIO
plans required 2.8% more monitor units (MU), going
from an average of 492MU per 2Gy fraction in the 10
clinical plans to 506, suggesting that additional MLC
Table 2 Automatic Interactive Optimizer (AIO) and clinical plan results
Plan Clinical Nominal AIO AIO OLD= 25†† AIO OLD= 75†† AIO 3 objectives/OAR|| AIO 6 objectives/OAR|| AIO T = 7.5s¶ AIO T = 30s¶
PTVB V95* (%) 99.1 ± 0.2 98.9 ± 0.5 99.5 ± 0.2 97.5 ± 1.2 99.2 ± 0.5 98.9 ± 0.5 98.7 ± 0.6 98.5 ± 0.9
PTVB V107* (%) 1.1 ± 1.4 1.2 ± 1.6 0.5 ± 0.6 3.4 ± 3.6 0.5 ± 0.7 1.1 ± 1.2 1.9 ± 1.9 1.6 ± 1.6
PTVE V95* (%) 98.2 ± 1.1 97.7 ± 0.7 98.7 ± 0.6 96.0 ± 1.6 98.3 ± 1.0 97.8 ± 1.0 97.4 ± 1.0 97.3 ± 1.0
PTVE V107* (%) 14.5 ± 3.8 13.0 ± 5.4 9.5 ± 4.6 16.5 ± 6.2 10.3 ± 4.7 12.2 ± 5.0 13.7 ± 5.6 13.6 ± 5.1
Max dose (Gy) Spinal Cord 39.0 ± 3.7 39.1 ± 4.1 38.3 ± 4.0 39.8 ± 3.7 38.5 ± 4.2 38.8 ± 4.0 39.0 ± 3.8 38.3 ± 4.9
Brainstem 37.7 ± 7.7 37.3 ± 8.0 37.7 ± 8.3 38.8 ± 7.8 37.0 ± 7.2 37.6 ± 8.3 37.0 ± 7.9 37.5 ± 8.3
Mean dose (Gy) Contralateral Parotid 19.6 ± 5.6 18.7 ± 5.7 21.4 ± 6.9 17.6 ± 5.3 21.4 ± 6.7 19.5 ± 6.0 18.5 ± 5.5 19.0 ± 5.9
Ipisilateral Parotid 31.2 ± 8.1 29.9 ± 8.4 32.0 ± 8.5 27.5 ± 7.1 32.1 ± 8.7 30.5 ± 8.3 29.5 ± 7.9 29.8 ± 8.1
Contralateral Submandibular 31.2 ± 7.4 29.6 ± 8.0 34.0 ± 8.6 27.7 ± 7.3 33.9 ± 8.6 30.6 ± 8.3 29.4 ± 7.0 30.5 ± 7.4
Oral Cavity 28.6 ± 7.0 24.7 ± 7.9 26.7 ± 8.7 23.6 ± 7.6 27.0 ± 10.3 25.6 ± 8.3 24.2 ± 6.9 26.1 ± 7.4
Compsal
† 26.2 ± 5.5 25.0 ± 5.8 27.7 ± 6.5 24.2 ± 5.3 27.8 ± 6.2 25.8 ± 5.9 24.7 ± 5.4 25.2 ± 5.7
Compswal
† 28.7 ± 8.0 23.1 ± 8.7 27.0 ± 9.5 21.7 ± 8.7 26.7 ± 9.5 23.8 ± 9.2 22.5 ± 8.8 23.4 ± 8.7
AIO and clinical plan results averaged over all 10 patients using different AIO settings. Clinically acceptable doses to the brainstem and spinal cord were achieved in all plans.
Abbreviations:
*PTVB, PTVE, PTVT: Boost, elective, transition planning target volumes, respectively.
†Compsal / Compswal: Composite salivary glands / Composite swallowing muscles.
††AIO OLD = 25/75: AIO plan using an objective-line distance (OLD) of 25/75 pixels, a pause time of 15 seconds and 9 objectives per OAR.
||AIO 3/6 objectives per OAR: AIO plan using 3/6 objectives per OAR, a pause time of 15 seconds and an OLD of 50 pixels.
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sparing.
Figure 5 shows typically resulting DVH-lines and dose
distributions of a nominal AIO plan (triangles) and clin-
ical plan (rectangles) for patient 2. Using AIO, Dsal and
Dswal decreased by 2.3 and 5.7Gy, respectively while ap-
proximately equal coverage of the boost and elective
PTVs was obtained.Figure 5 DVH-lines and dose distributions of an automatic interactive
an AIO (dashed lines) and clinical (solid lines) plan for patient 2. Mean dose
decreased while approximately equal coverage of the boost and elective P
distributions on the level of the salivary glands while C) shows the dose diRunning AIO five times on a single patient showed
variations in Dsal and Dswal no greater than 0.9% and
2.0%, respectively. V95 of PTVB and PTVE ranged from
98.6-99.0% and 97.1-97.7% respectively, while V107
ranged from 0.5-1.2% and 14.3-17.3%. For this patient,
the PTV coverage values were slightly lower than the in-
stitutional guidelines because the AIO plans were nor-
malized to receive the same mean PTVB dose as theoptimizer (AIO) plan and clinical plan. A) shows the DVH-lines of
to the composite salivary glands (red) and swallowing muscles (green)
TVs (magenta and cyan, respectively) was obtained. B) shows the dose
stributions on the level of the swallowing muscles.
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been solved by either adjusting the normalization by a
fraction of a percent, or by running an additional CPO
calculation while slightly increasing the priority on PTV
optimization objectives. The non-interactive optimization
of the nominal AIO plans of 5 patients resulted in PTVB/
PTVE V95% values within 0.6%/0.3% of their respective
nominal AIO plan, while DOC/Dsal/Dswal varied no more
than 0.3/0.4/0.8Gy.
Using 3 instead of 9 optimization objectives per OAR
was associated with an increase in DOC, Dsal and Dswal
by 2.3Gy, 2.8Gy and 3.6Gy compared to the nominal
AIO plan, respectively (Table 2), while PTV dose homo-
geneity improved. Running AIO with 6 objectives per
OAR resulted in similar PTV coverage and homogeneity
as the nominal plan, while DOC, Dsal and Dswal were re-
spectively 0.9Gy, 0.8Gy and 0.7Gy higher. Although an
OLD of 25 pixels improved V95/V107 of PTVB and
PTVE by 0.6/0.7% and 1.0/3.5%, respectively, DOC/Dsal/
Dswal values increased by respectively 2.0/2.7/3.9Gy. The
opposite was noticed using an OLD of 75 pixels, which
degraded V95/V107 of PTVB and PTVE by 1.4%/2.2%
and 1.7%/3.5%, respectively, while DOC/Dsal/Dswal de-
creased by 1.1/0.8/1.4Gy.
Changing pause times of the AIO had little impact on
the PTV coverage/homogeneity and OAR sparing. On
average, AIO plans with a T = 7.5s achieved slightly
lower OAR doses relative to T = 15s, while T = 30s in-
creased them. This increase was associated with a
decrease in average optimization time, which was ap-
proximately 56, 32 and 16 minutes for T values of 7.5,
15 and 30 seconds using an Intel® Xeon® E2520 2.40Ghz
CPU in combination with a distributed calculation grid.
Although the magnitude was influenced by the complex-
ity of the patient, the number AIO iterations (steps 4 to
6, Figure 3) decreased for increasing T values. For pa-
tient 1 for example, AIO performed 85, 50 and 15 itera-
tions using pause times of 7.5, 15 and 30 seconds,
respectively.
Discussion
This study presented an initial evaluation of our in-
house developed automatic interactive optimizer (AIO).
AIO was designed to automate our interactive
optimization protocol for head and neck cancer using
the Eclipse treatment planning system in order to im-
prove plan quality and consistency. Under the planning
constraints posed during optimization by the minimum/
maximum dose objectives on the PTVs and single point
dose objectives on serial OARs (e.g. spinal cord and
brainstem), AIO gradually positions the optimization ob-
jectives of parallel OARs (e.g. salivary glands, swallowing
muscles and oral cavity) at lower dose values throughout
the optimization process. Compared to the clinical plans,nominal AIO plans achieved substantially improved spar-
ing of the swallowing muscles and oral cavity, although a
small decrease in PTV dose homogeneity was found in
some patients, which was considered clinically acceptable
[17,26]. On the other hand, if it is desired, then with min-
imal loss in OAR sparing, the PTV homogeneity can be
improved after the AIO optimization by running a rela-
tively short (non-interactive) CPO with higher priorities
on the PTV optimization objectives. It is important to
state that the use of AIO does not result in any changes
in the quality assurance process. Even though AIO re-
sulted in dosimetric improvements over clinical plans, the
final DVHs and dose distributions should still be routinely
evaluated by the planning dosimetrist, radiation oncologist
and physicist, prior to acceptance for treatment. This is no
different from treatment plans created manually or using
different automatic planning approaches.
Once AIO is running, it is fully automated, thereby
allowing the planner to invest time in other activities
while the optimization is being performed. Running AIO
optimizations in a virtual machine (Oracle VirtualBox;
http://www.virtualbox.org) allows the user to retain con-
trol of their cursor. They can therefore continue using
their PC while AIO is running. A virtual machine also
allows a custom screen resolution to be defined. Larger
resolutions may prevent potential overlap of the
optimization objectives during optimization, which leads
to suboptimal placement.
The effect of changing several user-definable AIO pa-
rameters was investigated and showed: 1) The selected
objective-line distance (OLD) influences the trade-off
between PTV dose homogeneity and OAR sparing.
These results can be expected because in PRO, increas-
ing or decreasing the OLD will relatively increase or de-
crease the cost of these OAR optimization objectives,
compared to the PTV objectives. 2) An increased num-
ber of optimization objectives generally improved OAR
sparing because a reduction in OAR doses was attempted
at a greater range of structure volumes. 3) The desired bal-
ance between optimization time and resulting plan quality
is determined by the chosen value of T. Larger values for
T resulted in less AIO iterations and in effect, the
optimization objectives were not placed at a constant
distance from their DVH-line at all times. Lower values of
T increase the number of AIO iterations and optimization
time, allowing the optimizer in theory to minimize the
cost function better. However, no marked improvement
was noted using T = 7.5s instead of 15s in this study.
Nominal AIO plans, generated with an OLD of 50 pixels,
9 optimization objectives per OAR and a T value of 15 sec-
onds, provided a good balance between optimization time,
OAR sparing and PTV dose homogeneity, and would
therefore provide a reasonable starting point for treatment
planning. The present results can also be generalized to
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‘grid’ of optimization objectives that was used (Figure 4A)
for example, indicates that AIO does not need a proper ini-
tial prediction of the objective starting locations to obtain
high quality plans, as long as the optimization objectives
are repositioned when the DVH-lines appear in the
optimization window. This assumption was validated by
re-optimizing the nominal AIO plans of 5 patients non-
interactively, using the final placement of the interactively
determined optimization objectives. The resulting plans
provided similar OAR sparing to the interactively opti-
mized AIO plans.
AIO was designed to automate interactive optimization
in the Eclipse TPS. We do not perceive this as a weak-
ness, as many automated planning solutions will ultim-
ately be vendor or TPS specific. However, since VMAT
optimization algorithms generally start with coarse
MLC configurations that get progressively finer as the
optimization progresses in one way or another, the core
concept of AIO, pushing OARs to lower doses through-
out the optimization process while the MLC apertures
are being defined, may also be transferable to different
TPS’s. Although AIO was only used in combination with
our clinical OAR and PTV optimization priorities so that
it generated plans fulfilling our clinical plan acceptance
criteria, we expect it to work equally well for other cri-
teria by adjusting the optimization priorities for PTVs
and the OLD. Running the same plan several times on
the same patient, AIO demonstrated a satisfactory degree
of consistency in OAR sparing and PTV dose homogen-
eity, demonstrating the reproducibility of the automated
optimization approach [26]. Because of the consistent
placement of the optimization objectives throughout the
optimization, we expect that AIO optimized plans are
well suited for treatment planning comparisons and plan-
ning studies where generally the user dependency of set-
ting and interacting with parameters can substantially
influence plan results [1].
Some potential limitations deserve comment. The
present study focused on the evaluation of AIO for
VMAT head and neck cancer planning. This was be-
cause VMAT is our standard delivery method for inten-
sity modulation and head and neck is one of the sites
where planners have to routinely deal with many differ-
ent OARs during interactive optimization. We did not
use the latest version of PRO. The version used in the
study (v10.0.28) is the one that is clinical use in our de-
partment. Preliminary tests indicate that AIO can also
be used with newer versions of PRO (11.0.31–13.5.10).
The current analysis investigated replacing manual inter-
action with software-controlled interaction for a particu-
lar planning strategy in which constant OLD are used
and priorities are held constant. This was done to repli-
cate our current institutional planning strategy. Thisstrategy also requires that the user knows the input pri-
orities that generally result in acceptable plans for the
majority of patients. We have used a standard set of pri-
orities for PTV and OAR, derived from our clinical prac-
tice, and we have not attempted to investigate the
influence of applying different priorities. Although AIO
has been specifically designed to reduce mean doses of
OARs, other planning strategies (e.g. focused on high or
low dose reduction) can also be incorporated. AIO was
designed to automate an important step in planning, it
does not automate the complete planning process.
Optimality of a plan may depend on more than the
optimization alone: the number of (partial) arcs [27],
chosen collimator angles, isocenter positions and jaw
settings, all which have to be input by the user, may also
influence the achieved plan dosimetry. In addition, we
recognize that there may be selected cases where plan-
ning teams may wish to use manual interaction. The
use of AIO does not prohibit switching to manual
optimization if desired.
Another automated planning solution described in the
literature is automated multi-criteria optimization, typic-
ally using a ‘wish list’ that contains PTV and OAR
optimization priorities and weights. For every OAR,
weightings are successively increased until either the re-
quired OAR sparing is achieved or the specified PTV
dose homogeneity/sparing of a higher prioritized OAR is
compromised [14-16]. The downside of this approach
could be that it prevents reduction of dose to low priori-
tized OAR, even though a substantial reduction could be
obtained with only a minor increase in dose to a higher
prioritized OAR. This does not occur when using AIO
because, apart from the optimization objectives that are
assigned, all the optimization objectives are continuously
pushed to lower doses. This is illustrated in a patient
where AIO decreased the mean dose of three different
swallowing muscles by 5.5Gy, while increasing mean
dose to the contralateral submandibular gland by 1.8Gy.
Although the clinician should decide whether this is
trade-off is deemed acceptable, it illustrates that a small
increase in dose to a single OAR may lead to a larger
dose reduction in multiple OARs.
Conclusions
The present report described the development and ini-
tial evaluation of AIO, automating and improving the
interactive optimization process in the Eclipse TPS. AIO
consistently allows the user to more fully exploit the
potential of interactive optimization in Eclipse. Import-
antly, this intermediate interface requires no modifica-
tion of the TPS. Preliminary testing shows that AIO can
deliver dosimetric improvements over manually optimized
head and neck plans. AIO has been clinically implemented
for head and neck treatment planning.
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